i realized i would have to dump my heinz and bristol meyers.est my fund dropped by more than 10%, i would have to open the doors and let people out of their contract noticed each day my stocks sank and sank because it was filled with best of breed finally we booted all of my faves and quickly got to even. if you want to perform on a daily basis, you got to take action you can't just sit there and get your head handed to you. this rotation game is not one that you can play at home. here is why. as that year progressed, the economy got hotter and hotter and these stocks kept getting higher and higher. and at a certain point things got too hot. and the next thing you know, the stock market crashed all of the cyclical plays were decimated. so were bristol meyer and heinz. and they snapped right back. so let's come back to the show itself i have now told you to use an index fund no matter what and buy individual stocks with mad money using it the right way and not the wrong way. how rotation can derail the best of the best. we try to explain right u

. >>> bristol meyers cancer drug has been approved by chinese.islato the medication is already approved in more than 60 other countries. bristol meyers shas climbed 2% to $54.80. >>> reuters say qualcomm's $44 billion merger with nxp co seuctors has not been approved by chinese regulators just yet. that r aort cameer bloomberg and a chinese publication said the deal was given the green light by china's ministry of commerce. shares were up a fraction. shares ofls qualcomm rose slightly to $59.86. >>> this week's market monitor is betting his three picks will continue to offer invesgrrs owth, income, and reasonable valuations. it's his first time with us as market. monit mike bailey, director of research. thanks for joining us tonigh >> thanks for having me. >> you want growth, income, and value. sounds llle you want it with these three. >> that's right. we're greedy. we want your cakend eat it, too. we think some of these oprtunities are out there. >> let's start first with your first pick, which would be the symbol rop, roper technology. and you

we've got news getting ahead again at bristol meyers. when it comes to keytruda.ou have to help me, david, there should be far more deals in health care there's too many look what the stocks have done one reat underperformers. now the banks can't merge because of the concentration issues but, david, these companies have been among the worst performers. i keep thinking i'm going to come in here and see a big deal involving a santa fe involving bristol meyers nothing. they areccepting their underperformance the way i never seen it. they accept their under performance like, wow, we're just not what we used to be. >> i think you're right an expectations there will be something.u mentioned amjen thae cash overseas. >> why aren't they doing something. why are we not seeing, david, the big bristol-myers pfizer that kind of thing. >> we have some other breaking news. >> what do we have >> notion tin addition to the mt boeing it's the territory opened by honeywell and united technologies we'll get to phil. >> reporter: boeing announced it's forming a joint venture with saf

a letter and the stock goes up huge it's almost like if you sent a letter to bristol meyers you can gett to 58 again, i think that the market wants to go higher and people are so kind of thinking okay what is going to happen because of trudeau, the shouting match with trudeau and the answer is the market doesn't care the market doesn't care. >> you mean the name calling they think it's noise. >> they think it's noise they think it's like, you know, when you're in back of class and the teacher says hey, why don't you share it with the whole class and they do and it goes, you know, why don't you share it with the whole class nothing. >> one thing to watch is apple's race toward a trillion dollar cap. >> yes now you're talking. >> $191.70 got to get to $202 and change. talking another, basically, another 6%. >> so last week there was a story citing sources -- it's hard to do with a straight face. citing sources that apple has cut back a lot of its orders now i have worked enough with apple that i have spoken to them and what they often say is can you believe that people still trade on thos

winner in that space out of this weekend and from previous data but you do have competitors in bristol meyers astazenca and we had the ceo on this morning and we asked him about that comparison that his chief scientific officer made saying ketruda and optiva are like coke and if you look at the totality of the data, the drugs are the same do you agree with that >> of course i wasn't there to hear exactly what the question was. >> it's pretty much exactly that >> but what i would say is, first of all, you can't really make a coke versusep comparison, because as is well known, i mean, these molecules are chemically quite different they're biologically different it's easy to see that there's a difference in their fundamental biology, and the question that's being asked is, well, clinically, is there a difference, and what i would say is at this point we have overall survival data in non-small cell lung cancer in the first lin setting. we first described that about two years ago for patients who had high levels of a particular biomarker called pdl-1 that was an extraordinary result, and since tha